Radiotherapy
An estimated 10%-60% of men who undergo primary RT for prostate cancer may experience a biochemical recurrence within 5 years (1). Depending on patient characteristics, risk stratification, and dose
There is a continued increasing hazard rate of biochemical failure after radiotherapy beyond 5 years (2)
Late distant metastases are more pronounced in prostate cancer patients with local failure after radiotherapy (3)
Unanswered questions
Salvage Cryotherapy
SCORE stands for Salvage Cryotherapy Registry Evaluation. As part of SCORE, approximately 800 men who have chosen salvage cryotherapy for prostate cancer recurrence will agree to share information about themselves.
Participation in SCORE does not alter treatment nor does it affect the risks or benefits of salvage cryotherapy. Participation in SCORE is completely anonymous; name and other personal identifiers are withheld from the national registry.
The information from SCORE is collected in a national registry so that prostate cancer doctors can improve their understanding of this treatment option (salvage cryotherapy). This information will serve as the basis for future medical publications and medical lectures. In addition, the data collected as part of SCORE will help men like yourself better understand the benefits & risks of salvage cryotherapy for prostate cancer recurrence.
To speak to a patient advocate about SCORE or salvage cryotherapy call 877-722-2796
If you need further information about this study. Please contact Al Barqawi MD